Protective role of lactic acid bacteria and yeasts as dietary carcinogen-binding agents – a review

Cuevas-González, Paúl F; González‐Córdova, Aarón F.; Vallejo-Córdoba, Belinda; Aguilar-Toalá, José E.; Hall, Felicia; Urbizo-Reyes, Uriel; Liceaga, Andrea M.; Hérnández-Mendoza, Adrian; Garcı́a, Hugo S.

doi:10.1080/10408398.2020.1813685

Cited by 21 publications

(7 citation statements)

References 175 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Increase antimutagenic activity [52,71,72]-Although this capability has largely been explored in the context of cancer [73], certain species of lactic acid microbiota can bind potent mutagens such as pyrolyzates [74,75] and heterocyclic amines [76,77] in the gut to decrease the mutagenic activity of these compounds. Reducing DNA damage reduces inflammation, protects the gut wall, increases mineral absorption, and suppresses osteoporosis [78].…”

mentioning

confidence: 99%

The Human Gut Microbiota: A Key Mediator of Osteoporosis and Osteogenesis

Seely

Kotelko

Douglas

et al. 2021

IJMS

View full text Add to dashboard Cite

An expanding body of research asserts that the gut microbiota has a role in bone metabolism and the pathogenesis of osteoporosis. This review considers the human gut microbiota composition and its role in osteoclastogenesis and the bone healing process, specifically in the case of osteoporosis. Although the natural physiologic processes of bone healing and the pathogenesis of osteoporosis and bone disease are now relatively well known, recent literature suggests that a healthy microbiome is tied to bone homeostasis. Nevertheless, the mechanism underlying this connection is still somewhat enigmatic. Based on the literature, a relationship between the microbiome, osteoblasts, osteoclasts, and receptor activator of nuclear factor-kappa-Β ligand (RANKL) is contemplated and explored in this review. Studies have proposed various mechanisms of gut microbiome interaction with osteoclastogenesis and bone health, including micro-RNA, insulin-like growth factor 1, and immune system mediation. However, alterations to the gut microbiome secondary to pharmaceutical and surgical interventions cannot be discounted and are discussed in the context of clinical therapeutic consideration. The literature on probiotics and their mechanisms of action is examined in the context of bone healing. The known and hypothesized interactions of common osteoporosis drugs and the human gut microbiome are examined. Since dysbiosis in the gut microbiota can function as a biomarker of bone metabolic activity, it may also be a pharmacological and nutraceutical (i.e., pre- and probiotics) therapeutic target to promote bone homeostasis.

show abstract

mentioning

confidence: 99%

The Human Gut Microbiota: A Key Mediator of Osteoporosis and Osteogenesis

Seely

Kotelko

Douglas

et al. 2021

IJMS

View full text Add to dashboard Cite

show abstract

“…Various species in the genera of Lactobacillus, Bifidobacterium, Streptococcus, Lactococcus, Bacillus, Streptococcus, Pediococcus, Enterococcus, Bacteroides, Akkermansia, Propionibacterium and Saccharomyces have been recognised as probiotics and the (Barros et al, 2019;Tenorio-Jim enez et al, 2020) through balancing the intestinal microflora, increasing nutrients bioavailability and generation of various bioactive compounds such as bacteriocins, short-chain fatty acids, exopolysaccharides, enzymes and vitamins (Hossain et al, 2017;Aguilar-Toal a et al, 2018;Indira et al, 2019). Additionally, it has been highlighted that probiotics can detoxify xenobiotics and hinder their toxicity through binding to these toxicants and employing enzymatic reactions (Khorshidian et al, 2016;Hossain et al, 2017;Cuevas-Gonz alez et al, 2020b). Detoxification properties of probiotics against mycotoxins, heavy metals, polycyclic aromatic hydrocarbons, heterocyclic aromatic amines, nitrosamine and pesticides have been investigated widely in recent years, and it has been elucidated that this protective activity is dependent on several factors such as strain type, medium pH, growth phase, toxicant structure and concentration (Yousefi et al, 2019;Khorshidian et al, 2020).…”

Section: Pesticide Residue In Food Products and Their Toxicological Effectsmentioning

confidence: 99%

Probiotics as potential detoxification tools for mitigation of pesticides: a mini review

Mohammadi

Shadnoush

Sohrabvandi

et al. 2020

Int J of Food Sci Tech

View full text Add to dashboard Cite

Pesticides play a key role in agriculture and food production by controlling the insects, weeds, plant pathogens and microbial contaminations. Although they are useful in some aspects, their inappropriate application can induce health problems including carcinogenicity, reproductive toxicity, neurodegenerative diseases and disruption of endocrine system. In this respect, efficient strategies should be applied to reduce pesticide residue in foodstuffs. Several methods have been proposed in food processing for reduction of pesticides residue. Recently, detoxification via microorganisms such as lactic acid bacteria and probiotics has been extensively studied and degradation of pesticides through hydrolytic enzymes has been introduced as the possible mechanism and it has been highlighted that some probiotics harbour pesticide-degrading genes. The aim of this review is to evaluate the efficacy of probiotics in detoxification of pesticides.

show abstract

“…As recently as 2020, a survey of global food crop contamination reported an incidence of 25% of mycotoxins above the EU and Codex limits ( Eskola et al, 2020 ). The potential toxic effects of mycotoxins including immunosuppression and carcinogenic effects have stimulated considerable research efforts aiming at reducing the mycotoxin levels in foods ( Corassin et al, 2013 ; Oliveira et al, 2014 ; Gummadidala et al, 2019 ; Cuevas-González et al, 2020 ; Gao et al, 2020 ). In particular, the aflatoxins (AFs) B 1 (AFB 1 ) and M 1 (AFM 1 ) were classified in Group 1 (human carcinogen) by the International Agency for Research on Cancer (2012) , while ochratoxin A (OTA) was categorized in Group 2B, probable carcinogen to humans ( International Agency for Research on Cancer, 1993 ).…”

Section: Introductionmentioning

confidence: 99%

Effect of Lactic Acid Bacteria Strains on the Growth and Aflatoxin Production Potential of Aspergillus parasiticus, and Their Ability to Bind Aflatoxin B1, Ochratoxin A, and Zearalenone in vitro

et al. 2021

View full text Add to dashboard Cite

The increased consumption of plant-based foods has intensified the concern related to mycotoxin intoxication. This study aimed to investigate the effect of selected lactic acid bacteria (LAB) strains on the growth of Aspergillus parasiticus NRRL 2999 and its production of aflatoxin (AF). The ability of the heat-killed (100°C for 1 h) LAB strains to bind aflatoxin M1 (AFM1) in milk and aflatoxin B1 (AFB1), ochratoxin A (OTA), and zearalenone (ZEN) in potassium phosphate buffer (PPB) was also evaluated in vitro. Ten LAB strains were tested individually, by inoculating them simultaneously with the fungus or after incubation of the fungus for 24 or 48 h at 25°C. Double layer yeast extract sucrose (YES) agar, de Man Rogosa and Sharpe (MRS) agar, and YES broth were incubated for 7 days at 25°C to follow the development of the fungus. Levilactobacillus spp. 3QB398 and Levilactobacillus brevis 2QB422 strains were able to delay the growth of A. parasiticus in YES broth, even when these strains were inoculated 24 h after the fungus. The inhibitory effect of these LAB strains was confirmed by the reduction of fungus colony size, suggesting dominance of LAB by competition (a Lotka-Voltera effect). The production of AFB1 by A. parasiticus was inhibited when the fungus was inoculated simultaneously with Lactiplantibacillus plantarum 3QB361 or L. plantarum 3QB350. No AFB1 was found when Levilactobacillus spp. 2QB383 was present, even when the LAB was inoculated 48 h after the fungus. In binding studies, seven inactivated LAB strains were able to promote a reduction of at least 50% the level of AFB1, OTA, and ZEN. This reduction varied depending on the pH of the PPB. In milk, however, only two inactivated LAB strains were able to reduce AFM1, with a reduction of 33 and 45% for Levilactobacillus spp. 3QB398 (Levilactobacillus spp.) and L. brevis 2QB422, respectively. Nevertheless, these results clearly indicate the potential of using LAB for mycotoxin reduction.

show abstract

Protective role of lactic acid bacteria and yeasts as dietary carcinogen-binding agents – a review

Cited by 21 publications

References 175 publications

The Human Gut Microbiota: A Key Mediator of Osteoporosis and Osteogenesis

The Human Gut Microbiota: A Key Mediator of Osteoporosis and Osteogenesis

Probiotics as potential detoxification tools for mitigation of pesticides: a mini review

Effect of Lactic Acid Bacteria Strains on the Growth and Aflatoxin Production Potential of Aspergillus parasiticus, and Their Ability to Bind Aflatoxin B1, Ochratoxin A, and Zearalenone in vitro

Contact Info

Product

Resources

About